Investigating PKD2 deficiency-associated cardiomyopathies using hESC-cardiomyocytes and bioengineered 3D ventricular cardiac tissue strips. [PDF]
Li J +10 more
europepmc +1 more source
Beyond Traditional Screening: The Future of Heart Failure Detection With Biomarkers and AI
Advancing HF Screening: Integrating Technology and Risk Factors Across Eras. This diagram provides a comprehensive review of the historical developments and projected trends of heart failure (HF) screening methodologies, with the prevalent risk factors for HF depicted at the base.
Xiaofeng Fang +9 more
wiley +1 more source
Don't raise your white flag facing a sea of red ones: when cardiac amyloidosis mimics hypertrophic cardiomyopathy. [PDF]
Grilli G +11 more
europepmc +1 more source
Genetic Biomarkers in the Risk Assessment of Sudden Cardiac Events: A Personalized Approach
Genetic insights into the risk assessment of sudden cardiac events. ABSTRACT Sudden cardiac events are the leading cause of death worldwide. Conventional risk stratification methods, which largely depend on clinical history, imaging, and electrocardiography, are usually inadequate for identifying high‐risk individuals, especially those without visible ...
Shrikant Verma +5 more
wiley +1 more source
"Burned-Out" Hypertrophic Cardiomyopathy: Overlap on Cardiac MRI With Other Nonischemic Cardiomyopathies. [PDF]
Wunderly K +3 more
europepmc +1 more source
GSK3β drives early diabetic tubulopathy via TFEB‐mediated mitochondrial dysfunction
Mitochondrial dysfunction, including mitochondrial biogenesis, mitophagy, dynamics and oxidative stress, occurs in the early stages of diabetic tubulopathy, which precede proteinuria and renal histological changes. GSK3β is a potential novel biomarker for the prediction of diabetic tubulopathy.
Lan Yao +10 more
wiley +1 more source
High-Risk Cardiomyopathy Genotypes and Arrhythmic Risk: LMNA, FLNC, RBM20, PLN and Desmosomal Genes in the ESC 2023 Era. [PDF]
Tetaj N +5 more
europepmc +1 more source
ABSTRACT One of the most serious complications associated with the use of the chemotherapeutic agent doxorubicin (DOX) is cardiomyopathy. Although cardioprotective drugs such as angiotensin receptor‐neprilysin inhibitors (ARNI) are used to prevent cardiomyopathy in DOX patients, no studies have reported the relationship between ARNI and endoplasmic ...
Mert Unvan +3 more
wiley +1 more source
T1 Mapping In Differentiating Healthy And Pathological Myocardium. [PDF]
Bozer Uludağ S +3 more
europepmc +1 more source
Merrill D, Benson, Noel R, Dasgupta
openaire +2 more sources

